(CMPX) Compass Therapeutics - Ratings and Ratios

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biopharmaceutical company specializing in the development of antibody-based therapeutics for oncology. The companys pipeline focuses on targeting key pathways involved in tumor growth and immune modulation. Its lead candidate, CTX-009, is a bispecific antibody designed to inhibit Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), two critical pathways involved in angiogenesis and tumor vascularization. CTX-471, another key candidate, is an IgG4 monoclonal antibody that acts as an agonist of CD137, a co-stimulatory receptor that enhances immune cell activation. Additionally, the company is developing CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, aiming to overcome resistance to checkpoint inhibitors. Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics is focused on advancing its pipeline through clinical trials to address unmet needs in oncology.

From a financial perspective, Compass Therapeutics operates with a market capitalization of $423.77 million USD. The companys price-to-book (P/B) ratio stands at 3.36, indicating a premium valuation relative to its book value. The price-to-sales (P/S) ratio is elevated at 498.56, reflecting investor confidence in its long-term growth potential despite current losses. The return on equity (RoE) is -34.51%, typical for a clinical-stage biotech company still in the development phase. On the technical side, the stock is trading at $2.92 with a 20-day average volume of 1,048,333 shares. The 20-day moving average (SMA 20) is $3.27, while the 50-day (SMA 50) and 200-day (SMA 200) averages are $2.48 and $1.69, respectively. The average true range (ATR) of 0.33 suggests moderate volatility.